Nexalin technology receives notice of allowance from the uspto for patent covering deep intracranial frequency stimulation (difs™) technology for opioid and other substance use disorders

Patent strengthens nexalin's intellectual property portfolio and highlights the potential of difs™ technology in addressing substance use disorders, including opioids, alcohol, cocaine and methamphetamine patent strengthens nexalin's intellectual property portfolio and highlights the potential of difs™ technology in addressing substance use disorders, including opioids, alcohol, cocaine and methamphetamine
NXL Ratings Summary
NXL Quant Ranking